Department of Internal Medicine, East Carolina University, Greenville, NC, USA.
Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA.
J Gen Intern Med. 2019 Nov;34(11):2427-2434. doi: 10.1007/s11606-019-05325-8. Epub 2019 Sep 5.
Approximately 20% of patients with atherosclerotic cardiovascular disease (ASCVD) suffer from depression.
To compare healthcare expenditures and utilization, healthcare-related quality of life, and patient-centered outcomes among ASCVD patients, based on their risk for depression (among those without depression), and those with depression (vs. risk-stratified non-depressed).
The 2004-2015 Medical Expenditure Panel Survey (MEPS) was used for this study.
Adults ≥ 18 years with a diagnosis of ASCVD, ascertained by ICD-9 codes and/or self-reported data. Individuals with a diagnosis of depression were identified by ICD-9 code 311. Participants were stratified by depression risk, based on the Patient Health Questionnaire-2.
A total of 19,840 participants were included, translating into 18.3 million US adults, of which 8.6% (≈ 1.3 million US adults) had a high risk for depression and 18% had a clinical diagnosis of depression. Among ASCVD patients without depression, those with a high risk (compared with low risk) had increased overall and out-of-pocket expenditures (marginal differences of $2880 and $287, respectively, both p < 0.001), higher odds for resource utilization, and worse patient experience and healthcare quality of life (HQoL). Furthermore, compared with individuals who had depression, participants at high risk also reported worse HQoL and had higher odds of poor perception of their health status (OR 1.83, 95% CI [1.50, 2.23]) and poor patient-provider communication (OR 1.29 [1.18, 1.42]).
The sample population includes self-reported diagnosis of ASCVD; therefore, the risk of underestimation of the cohort size cannot be ruled out.
Almost 1 in 10 individuals with ASCVD without diagnosis of depression is at high risk for it and has worse health outcomes compared with those who already have a diagnosis of depression. Early recognition and treatment of depression may increase healthcare efficiency, positive patient experience, and HQoL among this vulnerable population.
约 20%的动脉粥样硬化性心血管疾病(ASCVD)患者患有抑郁症。
通过比较 ASCVD 患者(无抑郁患者)和抑郁患者(与风险分层无抑郁患者相比)的医疗支出和利用情况、与医疗保健相关的生活质量以及以患者为中心的结局,评估其抑郁风险。
本研究使用了 2004-2015 年医疗支出面板调查(MEPS)的数据。
≥18 岁、经 ICD-9 编码和/或自我报告数据确诊为 ASCVD 的成年人。通过 ICD-9 代码 311 确定患有抑郁症的个体。根据患者健康问卷-2(PHQ-2)对参与者进行抑郁风险分层。
共纳入 19840 名参与者,相当于 1830 万美国成年人,其中 8.6%(约 130 万美国成年人)有较高的抑郁风险,18%有临床诊断的抑郁症。在无抑郁的 ASCVD 患者中,与低风险相比,高风险患者的总支出和自付支出均增加(边际差异分别为 2880 美元和 287 美元,均 P<0.001),资源利用率更高,患者体验和医疗保健质量(HQoL)更差。此外,与患有抑郁症的个体相比,高风险参与者报告的 HQoL 更差,对健康状况的感知更差(OR 1.83,95%CI [1.50,2.23]),医患沟通更差(OR 1.29 [1.18,1.42])。
样本人群包括自我报告的 ASCVD 诊断;因此,不能排除低估队列规模的风险。
在没有诊断为抑郁症的 ASCVD 患者中,近 10 人有较高的抑郁风险,其健康结局比已经诊断为抑郁症的患者更差。在这一弱势群体中,早期识别和治疗抑郁症可能会提高医疗效率、改善患者体验和 HQoL。